BIOMAT Database Logo BIOMAT Database Logo

Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. 1995

U Nowak-Göttl, and B Rath, and M Binder, and J U Hassel, and J Wolff, and S Husemann, and J Ritter
Center of Pediatric Hematology and Oncology, University Hospital Münster, Germany.

A prospective longitudinal study was conducted to determine whether single-donor fresh frozen plasma (FFP) substitution was able to influence L-asparaginase-associated hypoproteinemia. Within a 36-month period, 20 of 42 children with ALL received a total of 42 prophylactic FFP doses at a median of 10 (5-20) mliter/kg when fibrinogen levels decreased to < 60 mg/dL and thrombin time was lengthened. Laboratory monitoring before, during and after FFP substitution showed no short-term improvements and demonstrated only a minimal increase in fibrinogen and alpha 2-antiplasmin. Plasma levels of antithrombin and plasminogen remained unchanged. Furthermore, administration of FFP had no influence on thrombin generation, the plasmin/alpha 2-antiplasmin complex or enhanced D-dimer formation.

UI MeSH Term Description Entries
D010949 Plasma The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION. Blood Plasma,Fresh Frozen Plasma,Blood Plasmas,Fresh Frozen Plasmas,Frozen Plasma, Fresh,Frozen Plasmas, Fresh,Plasma, Blood,Plasma, Fresh Frozen,Plasmas,Plasmas, Blood,Plasmas, Fresh Frozen
D010958 Plasminogen Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent. Profibrinolysin,Glu-Plasminogen,Glutamic Acid 1-Plasminogen,Glutamyl Plasminogen,1-Plasminogen, Glutamic Acid,Glu Plasminogen,Glutamic Acid 1 Plasminogen,Plasminogen, Glutamyl
D011486 Protein C A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
D001778 Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. Coagulation Disorders, Blood,Disorders, Blood Coagulation,Blood Coagulation Disorder,Coagulation Disorder, Blood,Disorder, Blood Coagulation
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005341 Fibrinolysin A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins. Plasmin,Fibrogammin,Glu-Plasmin,Protease F,Thrombolysin,Glu Plasmin
D000347 Afibrinogenemia A deficiency or absence of FIBRINOGEN in the blood. Fibrinogen Deficiency,Afibrinogenemia, Congenital,Congenital Afibrinogenaemia,Congenital Afibrinogenemia,Deficiency, Fibrinogen,Familial Afibrinogenemia,Hypofibrinogenemia, Congenital,Afibrinogenaemia, Congenital,Afibrinogenaemias, Congenital,Afibrinogenemia, Familial,Afibrinogenemias,Afibrinogenemias, Congenital,Afibrinogenemias, Familial,Congenital Afibrinogenaemias,Congenital Afibrinogenemias,Congenital Hypofibrinogenemia,Congenital Hypofibrinogenemias,Familial Afibrinogenemias,Fibrinogen Deficiencies,Hypofibrinogenemias, Congenital
D000933 Antifibrinolytic Agents Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders. Antifibrinolysin,Antifibrinolysins,Antifibrinolytic,Antifibrinolytic Agent,Antiplasmin,Antiplasmins,Antifibrinolytics,Plasmin Inhibitor,Plasmin Inhibitors,Agent, Antifibrinolytic,Agents, Antifibrinolytic,Inhibitor, Plasmin,Inhibitors, Plasmin
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D000979 alpha-2-Antiplasmin A member of the serpin superfamily found in plasma that inhibits the lysis of fibrin clots which are induced by plasminogen activator. It is a glycoprotein, molecular weight approximately 70,000 that migrates in the alpha 2 region in immunoelectrophoresis. It is the principal plasmin inactivator in blood, rapidly forming a very stable complex with plasmin. alpha 2-Plasmin Inhibitor,Serpin F2,alpha(2)-Plasmin Inhibitor,alpha-2 Antiplasmin,alpha 2 Antiplasmin,alpha 2 Plasmin Inhibitor

Related Publications

U Nowak-Göttl, and B Rath, and M Binder, and J U Hassel, and J Wolff, and S Husemann, and J Ritter
Hypofibrinogenemia and coagulation factor deficiencies with L-asparaginase treatment.
June 1971, Cancer,
U Nowak-Göttl, and B Rath, and M Binder, and J U Hassel, and J Wolff, and S Husemann, and J Ritter
Inefficacy of fresh frozen plasma therapy of mucopolysaccharidosis II.
November 1972, Pediatrics,
U Nowak-Göttl, and B Rath, and M Binder, and J U Hassel, and J Wolff, and S Husemann, and J Ritter
Fresh frozen plasma contains free asparagine and may replace the plasma asparagine pool during L-asparaginase therapy.
June 2008, Leukemia,
U Nowak-Göttl, and B Rath, and M Binder, and J U Hassel, and J Wolff, and S Husemann, and J Ritter
Fresh frozen plasma: Beyond coagulation factor content.
April 2022, Transfusion medicine (Oxford, England),
U Nowak-Göttl, and B Rath, and M Binder, and J U Hassel, and J Wolff, and S Husemann, and J Ritter
Cerebral infarction in a patient with acute lymphoblastic leukemia after fresh-frozen plasma replacement during L-asparaginase therapy.
December 1992, American journal of hematology,
U Nowak-Göttl, and B Rath, and M Binder, and J U Hassel, and J Wolff, and S Husemann, and J Ritter
Coagulation support: fresh frozen plasma versus clotting factor concentrate.
May 1998, Anaesthesia,
U Nowak-Göttl, and B Rath, and M Binder, and J U Hassel, and J Wolff, and S Husemann, and J Ritter
Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma.
April 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
U Nowak-Göttl, and B Rath, and M Binder, and J U Hassel, and J Wolff, and S Husemann, and J Ritter
Technical method. Fresh frozen cryosupernatant in place of fresh frozen plasma for broad spectrum coagulation factor replacement.
April 1985, Journal of clinical pathology,
U Nowak-Göttl, and B Rath, and M Binder, and J U Hassel, and J Wolff, and S Husemann, and J Ritter
Perioperative coagulation management--fresh frozen plasma.
March 2010, Best practice & research. Clinical anaesthesiology,
U Nowak-Göttl, and B Rath, and M Binder, and J U Hassel, and J Wolff, and S Husemann, and J Ritter
[Coagulation disorders during treatment with l-asparaginase preparations].
January 1998, Wiadomosci lekarskie (Warsaw, Poland : 1960),
Copied contents to your clipboard!